Yarrow Bioscience, Inc.(YARW)— Stock Profile, AI Score & Financials

Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated 2026-06-30.

Yarrow Bioscience, Inc. (YARW) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores YARW at 15.2/100 on a 32-signal composite quality model, placing it at rank #2,855 of 2,962 stocks — the bottom half of the AI-ranked universe. Based on the latest XBRL financial filings (Q2 2026), Yarrow Bioscience, Inc. reports quarterly revenue of $97.0K, net income of $-3.0M. Top institutional holders of YARW by reported 13-F value include ADAR1 Capital Management, Nantahala Capital Management, Lynx1 Capital Management, based on the most recent SEC filings. YARW trades on the Nasdaq exchange and files with the SEC under CIK 1566044. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate YARW daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Yarrow Bioscience, Inc. directly from SEC EDGAR.